Rocket


Overview
Financials
News + Filings
Key Docs
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Equillium, Inc. (EQ) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/05/2023 8-K Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Notice of Delisting or Failure to...
Docs: "OPEN MARKET SALE AGREEMENT SM",
"Equillium, Inc."
08/09/2023 8-K Quarterly results
Docs: "Equillium Reports Second Quarter 2023 Financial Results and Provides Corporate and Clinical Updates $48.4 million in cash at the end of Q2 2023 expected to provide operating runway into 2025 Fully prepaid and retired debt facility Authorized $7.5 million stock repurchase program"
05/25/2023 8-K Termination of a Material Definitive Agreement  Interactive Data
05/23/2023 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
05/11/2023 8-K Quarterly results
Docs: "Equillium Reports First Quarter 2023 Financial Results and Provides Clinical Updates $62.0 million cash balance at the end of Q1 2023 expected to provide operating runway into 2025 Presented Phase 1b EQUATE data in aGVHD highlighting rapid and durable rates of overall clinical response, clinical response associated with improved progression-free survival through one year, and steroid tapering of 99% at Day 169&#x200b"
04/06/2023 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing  Interact...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION"
03/23/2023 8-K Quarterly results
Docs: "Equillium Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate & Clinical Development Updates"
12/23/2022 8-K Termination of a Material Definitive Agreement, Submission of Matters to a Vote of Security Holders, Other Events, Financial ...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Equillium and Metacrine Mutually Agree to Terminate Definitive Merger Agreement"
12/14/2022 8-K Quarterly results
12/06/2022 8-K Quarterly results
11/14/2022 8-K Quarterly results
09/27/2022 8-K Investor presentation
Docs: "Investor Presentation"
09/26/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Consent of Ernst & Young LLP, independent registered public accounting firm",
"Audited consolidated financial statements of Metacrine and its subsidiary as of and for the years ended December 31, 2021 and 2020, and the unaudited interim financial statements of Metacrine and its subsidiary as of June 30, 2022 and for the six months ended June 30, 2022 and 2021",
"Unaudited pro forma condensed combined balance sheet for the Company and its subsidiaries and Metacrine and its subsidiary as of June 30, 2022 and unaudited pro forma condensed combined statements of operations and comprehensive loss for the Company and its subsidiaries and Metacrine and its subsidiary for the year ended December 31, 2021 and for the six months ended June 30, 2022",
"Updated Equillium disclosure"
09/06/2022 8-K Investor presentation
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549",
"Agreement and Plan of Merger, by and among Equillium, Inc., Metacrine, Inc., Equillium Acquisition Sub, Inc., and Triumph Merger Sub, Inc",
"Equillium to Acquire Metacrine in All-Stock Transaction",
"Investor Presentation"
08/15/2022 8-K Quarterly results
05/25/2022 8-K Quarterly results
05/12/2022 8-K Quarterly results
05/09/2022 8-K Quarterly results
04/25/2022 8-K Other Events  Interactive Data
03/23/2022 8-K Quarterly results
Docs: "Equillium Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate & Clinical Development Updates Announced positive topline data from EQUATE study of itolizumab in first-line aGVHD Initiated EQUATOR Phase 3 study of itolizumab in first-line aGVHD Presented interim safety data and reduction in proteinuria from the EQUALISE study of itolizumab in lupus patients Acquired Bioniz Therapeutics, adding two first-in-class clinical-stage assets to pipeline and proprietary product discovery platform"
03/04/2022 8-K Quarterly results
03/02/2022 8-K Quarterly results
02/16/2022 8-K Investor presentation
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETED ASTERISKS, HAS BEEN OMITTED BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM IF PUBLICLY DISCLOSED AGREEMENT AND PLAN OF MERGER by and among Equillium, Inc.; Project JetFuel Merger Sub, Inc.; Bioniz Therapeutics, Inc. and Kevin Green, as the Securityholders' Representative Dated as of February 14, 2022 TABLE OF CONTENTS PAGE SECTION 1. DESCRIPTION OF TRANSACTION 1 1.1 The Merger 1 1.2 Effect of the Merger 1 1.3 Closing; Effective Time 2 1.4 Certificate of Incorporation and Bylaws; Directors and Officers 2 1.5 Conversion of Shares 2 1.6 Treatment of Company Options. 3 1.7 Further Action 3 1.8 Closing of the Company's Transfer Books 3 1.9 Exchange/Payment 4 1.10 Post-Closing Adjust...",
"Equillium Acquires Bioniz Therapeutics Significantly Expanding Pipeline of Novel Immunomodulatory Drug Candidates",
"Corporate Presentation"
11/10/2021 8-K Quarterly results
Docs: "Equillium Reports Third Quarter 2021 Financial Results and Provides Clinical Development Updates Announced plans to initiate a pivotal study of itolizumab in first-line treatment of acute graft-versus-host disease Reported decrease in proteinuria observed in subgroup of patients with lupus following two doses of itolizumab Reported interim safety data from first cohort of asthma patients in Phase 1b EQUIP study Company reaffirms guidance for EQUIP Phase 1b topline data in Q4 2021, and updates guidance to commence acute GVHD pivotal study in early 2022 and for interim data from EQUALISE Phase 1b Type B lupus nephritis patients to mid-2022"
08/10/2021 8-K Quarterly results
07/12/2021 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Equillium Announces Plans to Initiate Phase 3 Pivotal Study of Itolizumab in First-line Treatment of Acute Graft-Versus-Host Disease Following End-of-Phase 1 Meeting with the FDA Single pivotal Phase 3 study in acute graft-versus-host disease to support filing of biologics license application On track to initiate study in Q4 2021"
06/14/2021 8-K Quarterly results
06/11/2021 8-K Quarterly results
06/10/2021 8-K Quarterly results
06/07/2021 8-K Quarterly results
05/28/2021 8-K Quarterly results
05/13/2021 8-K Quarterly results
03/30/2021 8-K Quarterly results
03/24/2021 8-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy